MERS antibodies produced in cattle safe, treatment well tolerated in phase 1 trial
(NIH/National Institute of Allergy and Infectious Diseases) An experimental treatment developed from cattle plasma for Middle East respiratory syndrome (MERS) coronavirus infection shows broad potential, according to a small clinical trial led by National Institutes of Health scientists and their colleagues. The treatment, SAB-301, was safe and well tolerated by healthy volunteers, with only minor reactions documented.
A U.S. appeals court on Friday rejected a novel strategy adopted by drug company Allergan PLC to shield patents from review by an administrative court by transferring them to a Native American tribe.
Condition: Blue Light Damage Intervention: Other: Marvel AM Sponsor: Allergan Not yet recruiting
Condition: HIV Infections Interventions: Device: Dapivirine vaginal ring; Drug: FTC/TDF Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Eosinophilic esophagitis (EoE) is when there is a buildup of eosinophils (a type of white blood cell) in the esophagus (the tube that links your mouth and stomach). The buildup causes irritation and scarring. EoE is the result of an allergy to certain foods and is a lifelong health issue.
ConclusionThis study provides a new insight into the relationship between allergic symptoms and childhood acute lymphoid leukaemia, by suggesting this inverse association could be limited to children carrying certain genetic polymorphisms. If confirmed, these results could help better understand the biological mechanisms involved in the development of childhood acute lymphoid leukaemia.
This study aimed to evaluate how polymorphisms in DAD1 and OXA1L are associated with asthma and markers of atopy in individuals from the Salvador cohort of the SCAALA (Social Change Asthma and Allergy in Latin America) program. The DNA of 1220 individuals was genotyped using the Illumina 2.5 Human Omni Bead chip. Logistic regression analyses were performed with PLINK 1.9 software to verify the association between DAD1 and OXA1L polymorphisms and asthma and atopic markers, adjusted for sex, age, helminth infections and ancestry markers, using an additive model. The DAD1 and OXA1L genes were associated with some of the evalu...
CONCLUSION: Compounds V and VI were demonstrated viral inhibition towards Human cytomegalovirus, whereas cyclopropylquinoline derivative IV towards Rift Valley fever virus and Tacaribe virus. Additionally, cyclopropylquinoline derivative IV has displayed very good cytotoxicity against colon, breast and leukemia cell lines in vitro. PMID: 29792154 [PubMed - as supplied by publisher]
(NIH/National Institute of Allergy and Infectious Diseases) Enrollment has begun in an early-stage clinical trial testing the safety of two human monoclonal antibodies (mAbs) designed to treat people infected with Middle East respiratory syndrome coronavirus (MERS-CoV). The trial is sponsored by the National Institute of Allergy and Infectious Diseases, part of NIH, and is funded in part by the Biomedical Advanced Research and Development Authority, part of the Office of the Assistant Secretary for Preparedness and Response, Department Health and Human Services.
(NIH/National Institute of Allergy and Infectious Diseases) NIH scientists and colleagues report that an experimental vaccine given six weeks before exposure to Middle East respiratory syndrome coronavirus (MERS-CoV) fully protects rhesus macaques from disease. The vaccine also generated potentially protective MERS-CoV antibodies in blood drawn from vaccinated camels. MERS-CoV, which causes pneumonia deep in the lungs, emerged in 2012 and has sickened more than 1,400 people and killed 500, mostly in the Middle East and Asia.
Antibody against MERS Transmission EM of MERS-CoV. Image courtesy of National Institute of Allergy and Infectious Diseases. Middle East Respiratory Syndrome (MERS) is a severe infection of the lower respiratory tract caused by the MERS coronavirus (MERS-CoV), which has been responsible for over 1,300 human infections and 500 deaths since...